Astrazeneca’s $85m Quell collaboration comes after Regeneron’s tie-up with Sonoma and Lilly’s deal with Trex.
Today’s collaboration with Life Edit is a return to the Danish group’s familiar small, early-stage deal strategy.
Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.
With Boehringer locked in, the Danish biotech wants more partners for monotherapies, combos and more.
The developer has two new collaborations in rare dystrophies, with Entrada and Tevard, but work is early and certain rivals are some way ahead.